Literature DB >> 23391614

Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease.

April D Lake1, Petr Novak, Petia Shipkova, Nelly Aranibar, Donald Robertson, Michael D Reily, Zhenqiang Lu, Lois D Lehman-McKeeman, Nathan J Cherrington.   

Abstract

Bile acids (BAs) have many physiological roles and exhibit both toxic and protective influences within the liver. Alterations in the BA profile may be the result of disease induced liver injury. Nonalcoholic fatty liver disease (NAFLD) is a prevalent form of chronic liver disease characterized by the pathophysiological progression from simple steatosis to nonalcoholic steatohepatitis (NASH). The hypothesis of this study is that the 'classical' (neutral) and 'alternative' (acidic) BA synthesis pathways are altered together with hepatic BA composition during progression of human NAFLD. This study employed the use of transcriptomic and metabolomic assays to study the hepatic toxicologic BA profile in progressive human NAFLD. Individual human liver samples diagnosed as normal, steatosis, and NASH were utilized in the assays. The transcriptomic analysis of 70 BA genes revealed an enrichment of downregulated BA metabolism and transcription factor/receptor genes in livers diagnosed as NASH. Increased mRNA expression of BAAT and CYP7B1 was observed in contrast to decreased CYP8B1 expression in NASH samples. The BA metabolomic profile of NASH livers exhibited an increase in taurine together with elevated levels of conjugated BA species, taurocholic acid (TCA) and taurodeoxycholic acid (TDCA). Conversely, cholic acid (CA) and glycodeoxycholic acid (GDCA) were decreased in NASH liver. These findings reveal a potential shift toward the alternative pathway of BA synthesis during NASH, mediated by increased mRNA and protein expression of CYP7B1. Overall, the transcriptomic changes of BA synthesis pathway enzymes together with altered hepatic BA composition signify an attempt by the liver to reduce hepatotoxicity during disease progression to NASH.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23391614      PMCID: PMC3627549          DOI: 10.1016/j.taap.2013.01.022

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  44 in total

1.  Comparative hepatotoxicity of cholic acid, deoxycholic acid and lithocholic acid in the rat: in vivo and in vitro studies.

Authors:  N M Delzenne; P B Calderon; H S Taper; M B Roberfroid
Journal:  Toxicol Lett       Date:  1992-07       Impact factor: 4.372

2.  Bile Acids: The Good, the Bad, and the Ugly.

Authors:  Alan F. Hofmann
Journal:  News Physiol Sci       Date:  1999-02

Review 3.  Oxysterols in bile acid metabolism.

Authors:  Andrea Crosignani; Massimo Zuin; Mariangela Allocca; Marina Del Puppo
Journal:  Clin Chim Acta       Date:  2011-08-11       Impact factor: 3.786

4.  A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

Authors:  Vlad Ratziu; Victor de Ledinghen; Fréderic Oberti; Philippe Mathurin; Claire Wartelle-Bladou; Christophe Renou; Philippe Sogni; Marianne Maynard; Dominique Larrey; Lawrence Serfaty; Dominique Bonnefont-Rousselot; Jean-Philippe Bastard; Marc Rivière; Jean Spénard
Journal:  J Hepatol       Date:  2010-10-31       Impact factor: 25.083

5.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  Effect of bile duct ligation on bile acid composition in mouse serum and liver.

Authors:  Youcai Zhang; Ji-Young Hong; Cheryl E Rockwell; Bryan L Copple; Hartmut Jaeschke; Curtis D Klaassen
Journal:  Liver Int       Date:  2011-10-17       Impact factor: 5.828

7.  Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice.

Authors:  Jae-Seong Yang; Jin Taek Kim; Jouhyun Jeon; Ho Sun Park; Gyeong Hoon Kang; Kyong Soo Park; Hong Kyu Lee; Sanguk Kim; Young Min Cho
Journal:  PLoS One       Date:  2010-11-05       Impact factor: 3.240

Review 8.  New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).

Authors:  Rafeeq Ali; Kenneth Cusi
Journal:  Ann Med       Date:  2009       Impact factor: 4.709

Review 9.  Bile-acid-induced cell injury and protection.

Authors:  Maria-J Perez; Oscar Briz
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

10.  Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice.

Authors:  Lisa D Beilke; Lauren M Aleksunes; Ricky D Holland; David G Besselsen; Rick D Beger; Curtis D Klaassen; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2009-02-05       Impact factor: 3.922

View more
  64 in total

1.  Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.

Authors:  Cyrielle Caussy; Cynthia Hsu; Seema Singh; Shirin Bassirian; James Kolar; Claire Faulkner; Nikhil Sinha; Ricki Bettencourt; Naveen Gara; Mark A Valasek; Bernd Schnabl; Lisa Richards; David A Brenner; Alan F Hofmann; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2018-12-02       Impact factor: 8.171

2.  Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.

Authors:  B C Ferslew; C K Johnston; E Tsakalozou; A S Bridges; M F Paine; W Jia; P W Stewart; A S Barritt; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2015-03-15       Impact factor: 6.875

Review 3.  Bile acids in glucose metabolism and insulin signalling - mechanisms and research needs.

Authors:  Tiara R Ahmad; Rebecca A Haeusler
Journal:  Nat Rev Endocrinol       Date:  2019-10-15       Impact factor: 43.330

Review 4.  The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Monica D Chow; Yi-Horng Lee; Grace L Guo
Journal:  Mol Aspects Med       Date:  2017-05-05

5.  Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.

Authors:  Savannah Tallino; Megan Duffy; Martina Ralle; María Paz Cortés; Mauricio Latorre; Jason L Burkhead
Journal:  J Nutr Biochem       Date:  2015-05-15       Impact factor: 6.048

6.  Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury.

Authors:  Melina M Malinen; Izna Ali; Jacqueline Bezençon; James J Beaudoin; Kim L R Brouwer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-02-08       Impact factor: 4.052

Review 7.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

8.  A possible role of chenodeoxycholic acid and glycine-conjugated bile acids in fibrotic steatohepatitis in a dietary rat model.

Authors:  Xiaofang Jia; Yudai Suzuki; Hisao Naito; Husna Yetti; Kazuya Kitamori; Yumi Hayashi; Rina Kaneko; Mina Nomura; Yukio Yamori; Kei Zaitsu; Masashi Kato; Akira Ishii; Tamie Nakajima
Journal:  Dig Dis Sci       Date:  2014-01-22       Impact factor: 3.199

9.  Nonalcoholic Steatohepatitis Modulates Membrane Protein Retrieval and Insertion Processes.

Authors:  A L Dzierlenga; J D Clarke; N J Cherrington
Journal:  Drug Metab Dispos       Date:  2016-09-07       Impact factor: 3.922

Review 10.  The Contributing Role of Bile Acids to Metabolic Improvements After Obesity and Metabolic Surgery.

Authors:  Farnaz Fouladi; James E Mitchell; Joseph A Wonderlich; Kristine J Steffen
Journal:  Obes Surg       Date:  2016-10       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.